185 related articles for article (PubMed ID: 33809486)
21. Is it always necessary to apply botulinum toxin into the lower facial muscles in hemifacial spasm?: a randomized, single-blind, crossover trial.
Colakoglu BD; Cakmur R; Uzunel F
Eur Neurol; 2011; 65(5):286-90. PubMed ID: 21502764
[TBL] [Abstract][Full Text] [Related]
22. Long-term stable efficacy of botulinum toxin A in facial movement disorders with no need for increasing dose.
Badarny S; Ibrahim R; Susel Z; Zaina A; Nasar R; Badarny Y
Medicine (Baltimore); 2021 Jun; 100(25):e26481. PubMed ID: 34160460
[TBL] [Abstract][Full Text] [Related]
23. Hemifacial spasm through the last three decades: From etiology to efficacy and safety of long-term botulinum toxin treatment.
Herrero-Infante Y; Rodríguez-Sanz A; Máñez-Miró J; Vivancos-Matellano F
Clin Neurol Neurosurg; 2021 Apr; 203():106555. PubMed ID: 33662742
[TBL] [Abstract][Full Text] [Related]
24. Validation of a Chinese version of disease specific quality of life scale (HFS-36) for hemifacial spasm in Taiwan.
Huang YC; Fan JY; Ro LS; Lyu RK; Chang HS; Chen ST; Hsu WC; Chen CM; Wu YR
Health Qual Life Outcomes; 2009 Dec; 7():104. PubMed ID: 20034399
[TBL] [Abstract][Full Text] [Related]
25. A comparative crossover study on the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques.
Lolekha P; Choolam A; Kulkantrakorn K
Neurol Sci; 2017 Nov; 38(11):2031-2036. PubMed ID: 28884242
[TBL] [Abstract][Full Text] [Related]
26. Botulinum toxin type A in the treatment of hemifacial spasm: an 11-year experience.
Barbosa ER; Takada LT; Gonçalves LR; Costa RM; Silveira-Moriyama L; Chien HF
Arq Neuropsiquiatr; 2010 Aug; 68(4):502-5. PubMed ID: 20730300
[TBL] [Abstract][Full Text] [Related]
27. The effects of botulinum toxin A on ephaptic transmission in idiopathic hemifacial spasm.
Kurt T; Seçil Y; Gürgör N; Tokuçoğlu F; Beckmann Y; Ertekin C
Int J Neurosci; 2009; 119(11):2044-55. PubMed ID: 19863260
[TBL] [Abstract][Full Text] [Related]
28. Botulinum Toxin Treatment of Blepharospasm, Orofacial/Oromandibular Dystonia, and Hemifacial Spasm.
Karp BI; Alter K
Semin Neurol; 2016 Feb; 36(1):84-91. PubMed ID: 26866500
[TBL] [Abstract][Full Text] [Related]
29. Headache in hemifacial spasm patients.
Peeraully T; Tan SF; Fook-Chong SM; Prakash KM; Tan EK
Acta Neurol Scand; 2013 May; 127(5):e24-7. PubMed ID: 23311349
[TBL] [Abstract][Full Text] [Related]
30. Botulinum toxin therapy of hemifacial spasm: bilateral injections can reduce facial asymmetry.
Xiao L; Pan L; Li B; Zhou Y; Pan Y; Zhang X; Hu Y; Dressler D; Jin L
J Neurol; 2018 Sep; 265(9):2097-2105. PubMed ID: 29987587
[TBL] [Abstract][Full Text] [Related]
31. A Double-Blind, Placebo-Controlled Study of Appropriate Site of Botulinum Toxin Therapy in Hemifacial Spasm.
Jitpimolmard S; Thinkhamrop B; Tiamkao S; Arunpongpaisal S; Arayavichanon P; Kosuwan W; Jitpimolmard S; Sawanyawisuth K
Adv Ther; 2022 May; 39(5):2025-2034. PubMed ID: 35266085
[TBL] [Abstract][Full Text] [Related]
32. Low-Dose Neubotulinum Toxin A versus Low-Dose Abobotulinum Toxin A Injection for the Treatment of Cervical Dystonia: A Multicenter, 48-Week, Prospective, Double-Blinded, Randomized Crossover Design Study.
Kongsaengdao S; Arayawithchanont A; Samintharapanya K; Rojanapitayakorn P; Maneeton B; Maneeton N
Toxins (Basel); 2021 Oct; 13(10):. PubMed ID: 34678987
[TBL] [Abstract][Full Text] [Related]
33. Botulinum Toxin Type A to Improve Facial Symmetry in Facial Palsy: A Practical Guideline and Clinical Experience.
de Sanctis Pecora C; Shitara D
Toxins (Basel); 2021 Feb; 13(2):. PubMed ID: 33670477
[TBL] [Abstract][Full Text] [Related]
34. Hemifacial spasm: clinical characteristics of 321 Indian patients.
Batla A; Goyal C; Shukla G; Goyal V; Srivastava A; Behari M
J Neurol; 2012 Aug; 259(8):1561-5. PubMed ID: 22222858
[TBL] [Abstract][Full Text] [Related]
35. Clinical features and response to botulinum toxin in primary and secondary hemifacial spasm.
Pandey S; Jain S
Neurol India; 2018; 66(4):1036-1042. PubMed ID: 30038089
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of hemifacial spasm with botulinum A toxin].
Duzyński W; Sławek J
Neurol Neurochir Pol; 1998; 32 Suppl 1():61-9. PubMed ID: 9608555
[TBL] [Abstract][Full Text] [Related]
37. The validation of the disease-specific questionnaire for health-related quality of life in Thai patients with hemifacial spasm.
Setthawatcharawanich S; Aui-aree N; Limapichart K; Satirapunya P; Phabphal K
J Med Assoc Thai; 2008 Nov; 91(11):1691-7. PubMed ID: 19127791
[TBL] [Abstract][Full Text] [Related]
38. The role of the injection botulinum toxin A in cases of blepharospasm syndrome, hemifacial spasm and Meige's syndrome.
Bastola P; Chaudhary M; Agrawal JP; Shah DN
Kathmandu Univ Med J (KUMJ); 2010; 8(31):305-10. PubMed ID: 22610735
[TBL] [Abstract][Full Text] [Related]
39. Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study.
Kongsaengdao S; Maneeton N; Maneeton B
Neuropsychiatr Dis Treat; 2018; 14():1119-1124. PubMed ID: 29731634
[TBL] [Abstract][Full Text] [Related]
40. [Safety and efficacy of botulinum toxin in hemifacial spasm].
Mazlout H; Kamoun Gargouri H; Triki W; Kéfi S; Brour J; El Afrit MA; Chéour M; Kraiem A
J Fr Ophtalmol; 2013 Mar; 36(3):242-6. PubMed ID: 23270989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
